Frankensalmon and the FDA

by MARTHA ROSENBERG

Rockville, MD

The FDA says it has not decided about approving AquAdvantage Salmon yet, even though it held hearings about how to label the genetically engineered fish the day after hearings about if it should be approved.

But a lot of invited speakers didn’t get the memo.

Presenting to the Veterinary Medicine Advisory Committee (VMAC) last week, Yonathan Zohar, from the Center of Marine Biotechnology at the University of Maryland, extolled the "promise" of aquaculture and bashed Greenpeace and other groups who are against growing "fish in cages."

And, Alison Van Eenennaam, with the Department of Animal Science at University of California-Davis, declared during labeling hearings, that GE salmon "poses no additional risk," criticized the New York Times’ AquAdvantage Salmon coverage and laughed at peanut allergy labels. She also served on the veterinary committee advising the FDA, the previous day.

The AquAdvantage Salmon was created by inserting the coding sequence from a chinook salmon growth hormone gene, under control of an ocean pout gene, into wild Atlantic salmon. The resulting fish grows twice as fast as wild Atlantic salmon, reaching its full size in 18 months instead of three years.

Though the fish, all female, are 95 to 99 percent sterile, Boston-based AquaBounty Technologies’ (ABT), its developer, says eggs will be grown on Prince Edward Island in Canada and adults in Panama because the respective marine environments discourage survival of escapees.

The FDA has approved GE crops, genetically modified bovine growth hormone (BGH) used in milk and, last year, a goat with human genes to create a blood clotting drug. But the AquAdvantage Salmon is the first GE animal whose flesh will actually be eaten.

Because the AquAdvantage Salmon is affected by a "transformation event" and the injected DNA "imparts traits" to the animal, the salmon’s application is actually being treated as a "new animal drug approval," hence a vet committee.

Some say the public health orientation of the new top two at FDA, Commissioner Margaret Hamburg and Deputy Commissioner Joshua Sharfstein (who spoke twice) will spell a harsher climate for genetically engineered foods. The public is also becoming less GE friendly and rejected BGH in milk in 2006, 13 years after it received FDA approval.

But FDA staffers who spoke at the hearings read right out of AquaBounty Technologies’ playbook, creating distinctions between "risk," "hazard" and "harm" — ice is only a risk if you slip on it they pointed out — that made the fish appear safer.

FDA staffers also said the AquAdvantage Salmon had minimal impact on the "human environment" until the advisory committee asked as opposed to what other kind of environment whereupon the term was dropped.

FDA’s Eric Silberhorn itemized ABT’s redundant safety systems to prevent the escape of GE salmon — screens, floor drains, chemical containment, chlorine, nets — as written in the sponsor’s Environmental Assessment, prepared for the FDA, bringing to mind BP.

Why does the government present industry data on behalf of industry, some in the audience asked, and why is industry called the "sponsor" instead of "applicant"?

AquAdvantage Salmon were also said to be less "fit" if they escape though no one quoted the part of ABT’s Environmental Assessment report that says the salmon eat five times as much as wild salmon and have less fear of predators. (see: Jurassic Park)

The risk of bootleg AquAdvantage Salmon surfacing in unregulated Asian operations, even returning as imports like a "transgenic shrimp" Silberhorn says is reported in US food, would be handled with the labeling, control and inspection given any US drug, said staffers. Of course other nations, like Canada and Panama are "sovereign" and not bound by our laws, added FDA’s Larisa Rudenko.

Genetic Unknowns, Layers of Carcasses

While the FDA did not use the loaded terms drift and mutate (or Frankenfish) it did request a "durability" report from ABT to make sure nothing genetically untoward happens.

And its Center for Veterinary Medicine briefing report finds an unexpected and unwanted genetic "rearrangement" with the AquAdvantage Salmon which relocates the inserted genetic material from "the far upstream promoter regions" to a "downstream location relative to the growth hormone coding region." Oops. The loss of part of a "35 base repeat region" and possible duplication of another effect were also reported.

Asked by the committee if the genetic unknowns could create unanticipated events, Jeff Jones, a veterinarian presenter at the hearings, said the changes were "not subject to the hormone feedback system" in the fish and that the relocated genetic construct currently abuts "something that can’t be read."

Elsewhere in its report, the FDA finds low glucose levels and high incidences of jaw erosion, focal inflammation and insulin-like growth factor 1 (IGF-1) in the AquAdvantage Salmon but concludes, giving no evidence, they are not caused by the genetic engineering.

While the FDA report says ABT’s excessive culling of "abnormal" salmon may have "skewed" safety studies, it does not question ABT’s proposed method of disposing of salmon affected by the 3Ms, mutations, morbidity and mortality.

"As dead fish are deposited, they will be covered with caustic lime, followed by another layer of dead fish and caustic lime, etc., until the burial pit is ~0.5 m deep, at which point it will sealed with plastic and covered with soil," says ABT’s Environmental Assessment. "In the event that disposal capacity at the site is inadequate to handle the immediate or aggregate waste volume, alternative means of disposal will be sought."

Antibiotics, veterinary drugs and coded antibiotic resistance were barely mentioned at the hearings (though Zohar predicted egg farm like densities of up "80 to 100 per cubic meter for the GE salmon) — nor was the practice of harvesting wild fish to feed farmed fish (though one invited speaker actually promoted the practice.)

In fact there was only one meltdown in the FDA’s otherwise confident presentation and it concerned ABT’s allergy study whose, "technical flaws… so limit its interpretation that we can not rely on its results," says the FDA report.

When FDA food scientists Kathleen Jones and Kevin Greenlees presented the allergy research, which sought to establish safety levels with no number that would be unsafe, the advisory committee pounced.

"It’s as if you selected an allergen in goat meat and one in sheep meat and compare the two and found a difference," said Louisiana State University’s David F. Senior, who chaired the committee. "Who cares?"

"These studies are a bust," said another committee member, asking why they were not conducted again.

"I am not a statistician and she is not here today," retreated Jones, adding that the studies were absolutely "above board," though no one had suggested they weren’t.

"You’ve reached the limit of my statistical" knowledge said Larisa Rudenko.

And when James D. McKean with the Department of Veterinary Diagnostic and Production Animal Medicine at Iowa State University asked why one table showed a category of comparison salmon suddenly dropped as a lone, extra salmon seemed to appear out of nowhere, skewing the results, FDA’s Greenlees said, "It’s my fault" and "I apologize."

Many hope an apology for considering an approval of the AquAdvantage Salmon itself is forthcoming.

MARTHA ROSENBERG can be reached at: martharosenberg@sbcglobal.net

Like What You’ve Read? Support CounterPunch
August 31, 2015
Michael Hudson
Whitewashing the IMF’s Destructive Role in Greece
Conn Hallinan
Europe’s New Barbarians
Lawrence Ware
George Bush (Still) Doesn’t Care About Black People
Joseph Natoli
Plutocracy, Gentrification and Racial Violence
Franklin Spinney
One Presidential Debate You Won’t Hear: Why It is Time to Adopt a Sensible Grand Strategy
Dave Lindorff
What’s Wrong with Police in America
Louis Proyect
Jacobin and “The War on Syria”
Lawrence Wittner
Militarism Run Amok: How Russians and Americans are Preparing Their Children for War
Binoy Kampmark
Tales of Darkness: Europe’s Refugee Woes
Ralph Nader
Lo, the Poor Enlightened Billionaire!
Peter Koenig
Greece: a New Beginning? A New Hope?
Dean Baker
America Needs an “Idiot-Proof” Retirement System
Vijay Prashad
Why the Iran Deal is Essential
Tom Clifford
The Marco Polo Bridge Incident: a History That Continues to Resonate
Peter Belmont
The Salaita Affair: a Scandal That Never Should Have Happened
Weekend Edition
August 28-30, 2015
Randy Blazak
Donald Trump is the New Face of White Supremacy
Jeffrey St. Clair
Long Time Coming, Long Time Gone
Mike Whitney
Looting Made Easy: the $2 Trillion Buyback Binge
Alan Nasser
The Myth of the Middle Class: Have Most Americans Always Been Poor?
Rob Urie
Wall Street and the Cycle of Crises
Andrew Levine
Viva Trump?
Ismael Hossein-Zadeh
Behind the Congressional Disagreements Over the Iran Nuclear Deal
Lawrence Ware – Marcus T. McCullough
I Won’t Say Amen: Three Black Christian Clichés That Must Go
Evan Jones
Zionism in Britain: a Neglected Chronicle
John Wight
Learning About the Migration Crisis From Ancient Rome
Andre Vltchek
Lebanon – What if it Fell?
Charles Pierson
How the US and the WTO Crushed India’s Subsidies for Solar Energy
Robert Fantina
Hillary Clinton, Palestine and the Long View
Ben Burgis
Gore Vidal Was Right: What Best of Enemies Leaves Out
Suzanne Gordon
How Vets May Suffer From McCain’s Latest Captivity
Robert Sandels - Nelson P. Valdés
The Cuban Adjustment Act: the Other Immigration Mess
Uri Avnery
The Molten Three: Israel’s Aborted Strike on Iran
John Stanton
Israel’s JINSA Earns Return on Investment: 190 Americans Admirals and Generals Oppose Iran Deal
Bill Yousman
The Fire This Time: Ta-Nehisi Coates’s “Between the World and Me”
Scott Parkin
Katrina Plus Ten: Climate Justice in Action
Michael Welton
The Conversable World: Finding a Compass in Post-9/11 Times
Brian Cloughley
Don’t be Black in America
Kent Paterson
In Search of the Great New Mexico Chile Pepper in a Post-NAFTA Era
Binoy Kampmark
Live Death on Air: The Killings at WDBJ
Gui Rochat
The Guise of American Democracy
Emma Scully
Vultures Over Puerto Rico: the Financial Implications of Dependency
Chuck Churchill
Is “White Skin Privilege” the Key to Understanding Racism?
Kathleen Wallace
The Id(iots) Emerge
Andrew Stewart
Zionist Hip-Hop: a Critical Look at Matisyahu
Gregg Shotwell
The Fate of the UAW: Study, Aim, Fire